IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia.
Industry: Health Care
Latest Trade: $14.60 +0.72 (+5.2%)
First Day Return: +29.4%
Return from IPO: -13.3%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 01/12/2024 |
Offer Price | $16.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 8.0 |
Deal Size ($mm) | $129 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 02/01/2024 |
Offer Price | $16.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 8.0 |
Deal Size ($mm) | $129 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Jefferies |
TD Cowen |
more |
Company Data | |
---|---|
Headquarters | Los Altos, CA, United States |
Founded | 2019 |
Employees | 63 |
Website www.altoneuroscience.com |